[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy

Autor: Passamonti L 1, Rodríguez PV 2, Hong YT 2, Allinson KSJ 2, Bevan-Jones WR 2, Williamson D 2, Jones PS 2, Arnold R 2, Borchert RJ 2, Surendranathan A 2, Mak E 2, Su L 2, Fryer TD 2, Aigbirhio FI 2, O'Brien JT 2, Rowe JB 2.

Publikováno v: Neurology 90 (2018): e1989–e1996. doi:10.1212/WNL.0000000000005610
info:cnr-pdr/source/autori:Passamonti L 1, Rodríguez PV 2, Hong YT 2, Allinson KSJ 2, Bevan-Jones WR 2, Williamson D 2, Jones PS 2, Arnold R 2, Borchert RJ 2, Surendranathan A 2, Mak E 2, Su L 2, Fryer TD 2, Aigbirhio FI 2, O'Brien JT 2, Rowe JB 2./titolo:[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy./doi:10.1212%2FWNL.0000000000005610/rivista:Neurology/anno:2018/pagina_da:e1989/pagina_a:e1996/intervallo_pagine:e1989–e1996/volume:90

OBJECTIVE: We tested whether in vivo neuroinflammation relates to the distinctive distributions of pathology in Alzheimer disease (AD) and progressive supranuclear palsy (PSP). METHODS: Sixteen patients with symptomatic AD (including amnestic mild co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::7f7f925914cc02d6ee8075a7ea4b5ff3